Vimarsana
Biggest News Aggregation in the World

Page 8 - Alanh Auerbach News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alanh Auerbach. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alanh Auerbach Today - Breaking & Trending Today

Puma Biotechnology Reports Third Quarter 2022 Financial Results - Vimarsana News

Puma Biotechnology Reports Third Quarter 2022 Financial Results

Raises FY 2022 NERLYNX Net Product Revenue GuidanceLOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2022. Unless otherwise stated, all comparisons are for the third quarter of 2022 compared to the...

Puma Biotechnology, Inc.: Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium - Vimarsana News

Puma Biotechnology, Inc.: Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented updated findings from the Phase II SUMMIT basket trial of neratinib for EGFR exon 18-mutant non-small cell lung cancer

Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for - Vimarsana News

Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of updated findings from the Phase II SUMMIT basket trial of neratinib for HER2 (ERBB2)-mutant, metastatic cervical cancer at the 2022 European Society for Medical Oncology (ESMO) Congress,...

Puma Biotechnology, Inc.: Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022 - Vimarsana News

Puma Biotechnology, Inc.: Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of updated findings from the Phase II SUMMIT basket trial of neratinib for HER2 (ERBB2)-mutant, metastatic

Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference - Vimarsana News

Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at the hybrid H.C. Wainwright 24th Annual Global Investment Conference, which...